202 related articles for article (PubMed ID: 31432497)
1. Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: A systematic review and meta-analysis.
Deng Z; Qin Y; Wang J; Wang G; Lang X; Jiang J; Xie K; Zhang W; Xu H; Shu Y; Zhang Y
Clin Genet; 2020 Jan; 97(1):25-38. PubMed ID: 31432497
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
3. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
[TBL] [Abstract][Full Text] [Related]
4. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
[TBL] [Abstract][Full Text] [Related]
5. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
[TBL] [Abstract][Full Text] [Related]
6. Systematic immunohistochemical screening for mismatch repair and ERCC1 gene expression from colorectal cancers in China: Clinicopathological characteristics and effects on survival.
Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
PLoS One; 2017; 12(8):e0181615. PubMed ID: 28767665
[TBL] [Abstract][Full Text] [Related]
7. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
8. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W
World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
[TBL] [Abstract][Full Text] [Related]
10. Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy.
Zhao F; Li E; Shen G; Dong Q; Ren D; Wang M; Zhao Y; Liu Z; Ma J; Xie Q; Liu Z; Li Z; Gao L; Zhao J
J Gastroenterol; 2023 Jul; 58(7):622-632. PubMed ID: 37036516
[TBL] [Abstract][Full Text] [Related]
11. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
[TBL] [Abstract][Full Text] [Related]
12. Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study.
Zhao L; Fu Y; Niu P; Zhang F; Jiao F; Zhou X; Wu Z; Wang W; Luan X; Han X; He M; Guan Q; Li Y; Zhao D; Gao J; Chen Y
Oncologist; 2023 Oct; 28(10):e891-e901. PubMed ID: 37104872
[TBL] [Abstract][Full Text] [Related]
13. Tumor Budding
Karlberg M; Stenstedt K; Hallström M; Ragnhammar P; Lenander C; Edler D
Anticancer Res; 2018 Aug; 38(8):4713-4721. PubMed ID: 30061240
[TBL] [Abstract][Full Text] [Related]
14. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):844-8. PubMed ID: 25620482
[TBL] [Abstract][Full Text] [Related]
15. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.
Venderbosch S; Nagtegaal ID; Maughan TS; Smith CG; Cheadle JP; Fisher D; Kaplan R; Quirke P; Seymour MT; Richman SD; Meijer GA; Ylstra B; Heideman DA; de Haan AF; Punt CJ; Koopman M
Clin Cancer Res; 2014 Oct; 20(20):5322-30. PubMed ID: 25139339
[TBL] [Abstract][Full Text] [Related]
16. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
Koopman M; Kortman GA; Mekenkamp L; Ligtenberg MJ; Hoogerbrugge N; Antonini NF; Punt CJ; van Krieken JH
Br J Cancer; 2009 Jan; 100(2):266-73. PubMed ID: 19165197
[TBL] [Abstract][Full Text] [Related]
17. Evidence for an Association of ERCC1 Expression and Mismatch Repair Status with Overall Survival in Colorectal Cancer Patients.
Li P; Xiao ZT; Braciak TA; Ou QJ; Chen G; Oduncu FS
Oncol Res Treat; 2017; 40(11):702-706. PubMed ID: 29065415
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J; Ke G; Bi R; Wu X
J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
20. Tumor Budding and PDC Grade Are Stage Independent Predictors of Clinical Outcome in Mismatch Repair Deficient Colorectal Cancer.
Ryan É; Khaw YL; Creavin B; Geraghty R; Ryan EJ; Gibbons D; Hanly A; Martin ST; O'Connell PR; Winter DC; Sheahan K
Am J Surg Pathol; 2018 Jan; 42(1):60-68. PubMed ID: 29112018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]